- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Large cell neuroendocrine carcinoma.
Displaying page 1 of 2.
| EudraCT Number: 2015-005642-59 | Sponsor Protocol Number: AK-2015-LC-1 | Start Date*: 2016-02-23 | |||||||||||||||||||||
| Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET | |||||||||||||||||||||||
| Full Title: Phase II trial: uPAR-PET for prognostication in patients with non-small cell lung cancer and large cell neuroendocrine carcinoma of the lung | |||||||||||||||||||||||
| Medical condition: Non-small cell lung cancer and large cell neuroendocrine carcinoma of the lung | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2010-022273-34 | Sponsor Protocol Number: CRAD001KDE37 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: A multi-centric, open-label, phase II study investigating the combination of Afinitor with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) large cell lung c... | |||||||||||||
| Medical condition: large-cell neuroendocrine carcinoma of the lung | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002683-31 | Sponsor Protocol Number: TUD-ALPINE-077 | Start Date*: 2021-06-24 | ||||||||||||||||
| Sponsor Name:Technische Universität Dresden | ||||||||||||||||||
| Full Title: A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung | ||||||||||||||||||
| Medical condition: locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung (LCNEC) not eligible for curative treatment | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-000408-27 | Sponsor Protocol Number: GOIRC-02-2016 | Start Date*: 2016-10-20 | ||||||||||||||||
| Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | ||||||||||||||||||
| Full Title: Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC (NABSTER trial) | ||||||||||||||||||
| Medical condition: sensitive and refractory relapsed small cells lung cancer (SCLC) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-004989-25 | Sponsor Protocol Number: INCAGN1876-201 | Start Date*: 2017-09-28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Biosciences International Sàrl | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Phase 1: advanced or metastatic cervical cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma, melanoma (mucosal or cutaneous), Merkel cell carcinoma, mesothelioma, MSI-H colorectal... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) BE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-004163-12 | Sponsor Protocol Number: 2020-012-GLOB1 | Start Date*: 2021-11-04 | |||||||||||||||||||||||||||||||
| Sponsor Name:Hutchison MediPharma Limited | |||||||||||||||||||||||||||||||||
| Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-003226-27 | Sponsor Protocol Number: RG_10-151 | Start Date*: 2012-11-02 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma | |||||||||||||
| Medical condition: Metastatic Merkel Cell Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001111-12 | Sponsor Protocol Number: 1367.1 | Start Date*: 2015-06-12 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:SCS Boehringer Ingelheim Comm.V | ||||||||||||||||||||||||||||||||||||||
| Full Title: An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced, unresectable and/or metastatic solid tumours, which have failed with conventional treatment or for which no therapy of proven efficacy exists, or in patients who are not amenable to stand... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-003844-31 | Sponsor Protocol Number: H6Q-MC-S064 | Start Date*: 2007-11-28 | |||||||||||
| Sponsor Name:Eli Lilly and Company limited | |||||||||||||
| Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer | |||||||||||||
| Medical condition: Locally advanced or metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000528-42 | Sponsor Protocol Number: 0601 | Start Date*: 2008-07-17 | |||||||||||
| Sponsor Name:Poniard Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Controlled Phase III Trial of Picoplatin and Best Supportive Care (BSC) versus BSC Alone in Patients with Small Cell Lung Cancer (SCLC), Refractory or Progressive within Six Months of... | |||||||||||||
| Medical condition: Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) LV (Completed) HU (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-000339-21 | Sponsor Protocol Number: JK08.1.01 | Start Date*: 2022-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Salubris Biotherapeutics, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Unresectable Locally Advanced or Metastatic Cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-003432-37 | Sponsor Protocol Number: A005D-E01-201 | Start Date*: 2018-02-06 | |||||||||||||||||||||||||||||||
| Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||||||||||||||||||||||
| Full Title: Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor | |||||||||||||||||||||||||||||||||
| Medical condition: Malignancies known to overexpress Gastrin-Releasing Peptide Receptors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-005942-41 | Sponsor Protocol Number: GOIRC-05-2020 | Start Date*: 2022-01-12 | ||||||||||||||||
| Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | ||||||||||||||||||
| Full Title: A multicenter phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell n... | ||||||||||||||||||
| Medical condition: treatment-naïve patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2006-004945-40 | Sponsor Protocol Number: GEN204 | Start Date*: 2007-03-29 | |||||||||||
| Sponsor Name:Genmab A/S | |||||||||||||
| Full Title: A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Can... | |||||||||||||
| Medical condition: Stage IIIA-IIIB Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Completed) NL (Prematurely Ended) FR (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001013-16 | Sponsor Protocol Number: PRODIGE69 | Start Date*: 2020-07-20 |
| Sponsor Name:CHU DIJON | ||
| Full Title: FOLFIRINOX VERSUS PLATINUM - ETOPOSIDE AS FIRST LINE CHEMOTHERAPY FOR METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY ASSOCIATED WI... | ||
| Medical condition: METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004046-16 | Sponsor Protocol Number: IMC-F106C-101 | Start Date*: 2020-04-08 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Immunocore Ltd. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Pos... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers. Study IMC-F106C-101 will enroll participants with advanced cancers, including unresectable or metastatic melanoma, ovarian ca... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-020408-31 | Sponsor Protocol Number: I2I-MC-JMMG | Start Date*: 2010-11-10 | ||||||||||||||||
| Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
| Full Title: A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed and Cisplatin in Patients with Stage IV Non-small Cell Lung Cancer | ||||||||||||||||||
| Medical condition: • Histological diagnosis of Stage IV NSCLC other than predominantly squamous cell histology. • Mesothelioma in advanced or metastatic stage for whom the combination with pemetrexed and cisplatin i... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2006-004865-32 | Sponsor Protocol Number: ABC-2006-NSCLC-01 | Start Date*: 2008-05-23 | ||||||||||||||||
| Sponsor Name:Aktion Bronchialkarzinom e.V. | ||||||||||||||||||
| Full Title: Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study with Bevacizumab plus Erlotinib Or Gemcitabin/Cisplatin plus Bevacizumab | ||||||||||||||||||
| Medical condition: Prospective, randomized multi-center, open label phase II study to determine the activity of a non chemotherapy first line biological treatment with Erlotinib/Bevacizumab or Gemcitabin-Cisplatin/Be... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-001468-12 | Sponsor Protocol Number: PEN-221-001 | Start Date*: 2017-01-16 |
| Sponsor Name:Tarveda Therapeutics, Inc. | ||
| Full Title: A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing ad... | ||
| Medical condition: Somatostatin receptor 2 (SSTR2) expressing advanced cancers, including gastroenteropancreatic (GEP) cancer or lung cancer or thymus cancer or other NETs (Neuroendocrine tumour) or small cell lung c... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-002145-35 | Sponsor Protocol Number: ABC-2011-NSCLC-03 | Start Date*: 2013-06-14 | |||||||||||
| Sponsor Name:Aktion Bronchialkarzinom (ABC) e.V. | |||||||||||||
| Full Title: SELECT-A: TS stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV | |||||||||||||
| Medical condition: Non-squamous advanced Non-Small-Cell Lung-Cancer (Stage IV) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
